UNSPSC 51452007: Thiacetarsamide sodium

This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KW75J7708X. European Medicines Agency schedules Thiacetarsamide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10965MIG. Thiacetarsamide sodium generally arises in the molecular formula C11H10ASNO5S2.2NA. The term THIACETARSAMIDE SODIUM is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule thiacetarsamide sodium under HS 29309085.

As of Q4 2014, THIACETARSAMIDE SODIUM remains US FDA's Preferred Term for this commodity. Thiacetarsamide sodium bears US NLM identifiers UMLS ID C0521911 and NCI Concept Code C81557. SMILES: C1CC(CCC1C(=O)N)[AS](SCC(=O)[O-])SCC(=O)[O-].[NA+].[NA+].

UNSPSC 51452007 Thiacetarsamide sodium is a Commodity code that nominally covers a parasiticide pharmaceutical, but recent state and local opportunities show minimal alignment with this specific product. The code's recent activity instead reflects broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and pharmacy benefit program administration — suggesting the code may be misapplied to general pharmaceutical sourcing or that thiacetarsamide sodium itself sees little state and local government demand. State and local issuing bodies using related pharmaceutical codes include state health agencies, county health departments, and municipal fire and rescue services. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission represent state-level buyers; Seminole County, Florida and the City of Tampa represent local jurisdictions active in pharmaceutical and medical supply procurement.

Recent opportunities span Minnesota (MMCAP cooperative covering multiple states including Oregon), Texas, and Florida. The Minnesota Department of Administration issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through MMCAP, requiring NDC-specific submissions and cGMP/DSCSA compliance, with awards effective July 1, 2026. The Texas Health and Human Services Commission posted an RFI (due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The City of Tampa released an IFB (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, valued at $700,000, with a 5 percent bid discount for certified Small Local Business Enterprises. Seminole County, Florida solicited naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) with quarterly deliveries of 1,900 naloxone units and 800 deactivation systems annually. The code itself shows little direct relevance to current state and local procurement activity under its nominal product scope.